Literature DB >> 28167613

Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers.

Rosalie Sears1, Joe W Gray2.   

Abstract

Invasion and metastasis of a subset of aggressive luminal B breast cancers is driven by the concomitant inactivation of the RasGAPs DAB2IP and RASAL2. Inactivation of both proteins increases RAS activity and drives invasion, whereas inactivation of DAB2IP specifically promotes NF-κB-mediated epithelial-mesenchymal transition. Cancer Discov; 7(2); 131-3. ©2017 AACRSee related article by Olsen et al., p. 202. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28167613      PMCID： PMC5312830          DOI： 10.1158/2159-8290.CD-16-1423

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

1.  Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.

Authors:  Sarah Naomi Olsen; Ania Wronski; Zafira Castaño; Benjamin Dake; Clare Malone; Thomas De Raedt; Miriam Enos; Yoko S DeRose; Wenhui Zhou; Stephanie Guerra; Massimo Loda; Alana Welm; Ann H Partridge; Sandra S McAllister; Charlotte Kuperwasser; Karen Cichowski
Journal:  Cancer Discov       Date:  2016-12-14       Impact factor: 39.397

Review 2.  Breast cancer intrinsic subtype classification, clinical use and future trends.

Authors:  Xiaofeng Dai; Ting Li; Zhonghu Bai; Yankun Yang; Xiuxia Liu; Jinling Zhan; Bozhi Shi
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

3.  Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation.

Authors:  Jessica E Hutti; Adam D Pfefferle; Sean C Russell; Mayukh Sircar; Charles M Perou; Albert S Baldwin
Journal:  Cancer Res       Date:  2012-05-02       Impact factor: 12.701

4.  Ras activation in human breast cancer.

Authors:  F C von Lintig; A D Dreilinger; N M Varki; A M Wallace; D E Casteel; G R Boss
Journal:  Breast Cancer Res Treat       Date:  2000-07       Impact factor: 4.872

5.  An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.

Authors:  Junxia Min; Alexander Zaslavsky; Giuseppe Fedele; Sara K McLaughlin; Elizabeth E Reczek; Thomas De Raedt; Isil Guney; David E Strochlic; Laura E Macconaill; Rameen Beroukhim; Roderick T Bronson; Sandra Ryeom; William C Hahn; Massimo Loda; Karen Cichowski
Journal:  Nat Med       Date:  2010-02-14       Impact factor: 53.440

Review 6.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

Review 7.  Dragging ras back in the ring.

Authors:  Andrew G Stephen; Dominic Esposito; Rachel K Bagni; Frank McCormick
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

8.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Authors:  Moriah H Nissan; Christine A Pratilas; Alexis M Jones; Ricardo Ramirez; Helen Won; Cailian Liu; Shakuntala Tiwari; Li Kong; Aphrothiti J Hanrahan; Zhan Yao; Taha Merghoub; Antoni Ribas; Paul B Chapman; Rona Yaeger; Barry S Taylor; Nikolaus Schultz; Michael F Berger; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2014-02-27       Impact factor: 12.701

9.  Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.

Authors:  Lynn B Eckert; Gretchen A Repasky; Aylin S Ulkü; Aidan McFall; Hong Zhou; Carolyn I Sartor; Channing J Der
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

10.  TRAF2 is an NF-κB-activating oncogene in epithelial cancers.

Authors:  R R Shen; A Y Zhou; E Kim; J T O'Connell; D Hagerstrand; R Beroukhim; W C Hahn
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867
  10 in total
  10 in total

Review 1.  Targeting metabolism: A potential strategy for hematological cancer therapy.

Authors:  Xue Tang; Fen Chen; Li-Chun Xie; Si-Xi Liu; Hui-Rong Mai
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

Review 2.  Pumping the brakes on RAS - negative regulators and death effectors of RAS.

Authors:  Desmond R Harrell Stewart; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2020-02-10       Impact factor: 5.285

3.  B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.

Authors:  Thomas Reinheckel; Tilman Brummer; Martin Köhler; Sophia Ehrenfeld; Sebastian Halbach; Manuel Lauinger; Ulrike Burk; Nadine Reischmann; Shuofei Cheng; Corinna Spohr; Franziska Maria Uhl; Natalie Köhler; Kathrin Ringwald; Sandra Braun; Christoph Peters; Robert Zeiser
Journal:  Oncogene       Date:  2019-01-18       Impact factor: 8.756

4.  The expression and function of RASAL2 in renal cell carcinoma angiogenesis.

Authors:  Ke Hui; Yangyang Yue; Shiqi Wu; Yanan Gu; Bing Guan; Xinyang Wang; Jer-Tsong Hsieh; Luke S Chang; Dalin He; Kaijie Wu
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

Review 5.  Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis.

Authors:  Shian-Ren Lin; Ntlotlang Mokgautsi; Yen-Nien Liu
Journal:  Molecules       Date:  2020-05-20       Impact factor: 4.411

6.  The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.

Authors:  Jessica A Moerland; Di Zhang; Lyndsey A Reich; Sarah Carapellucci; Beth Lockwood; Ana S Leal; Teresa Krieger-Burke; Bilal Aleiwi; Edmund Ellsworth; Karen T Liby
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

7.  RASAL2 suppresses the proliferative and invasive ability of PC3 prostate cancer cells.

Authors:  Krishma Tailor; Joseph Paul; Somiranjan Ghosh; Namita Kumari; Bernard Kwabi-Addo
Journal:  Oncotarget       Date:  2021-12-21

8.  RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma.

Authors:  Yangyang Yue; Kaijie Wu; Weikun Qian; Zeen Zhu; Simei Zhang; Wunai Zhang; Weifan Zhang; Shuai Wu; Li Li; Zheng Wu; Qingyong Ma; Keping Xie; Zheng Wang
Journal:  Int J Biol Sci       Date:  2022-06-27       Impact factor: 10.750

Review 9.  RASAL2 Plays Inconsistent Roles in Different Cancers.

Authors:  Bolun Zhou; Wei Zhu; Xingjun Jiang; Caiping Ren
Journal:  Front Oncol       Date:  2019-11-13       Impact factor: 6.244

Review 10.  Role of RASA1 in cancer: A review and update (Review).

Authors:  Yanhua Zhang; Yue Li; Quanyue Wang; Bo Su; Hui Xu; Yang Sun; Pei Sun; Rumeng Li; Xiaochun Peng; Jun Cai
Journal:  Oncol Rep       Date:  2020-10-13       Impact factor: 3.906
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.